The Cancer Letter

Inside information on cancer research and drug development

In Brief

Andrew Mesecar named director of Purdue Institute for Cancer Research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Andrew Mesecar, Distinguished Professor of Biochemistry and the Walther Professor in Cancer Structural Biology, was named assistant vice president for research and director of the Purdue Institute for Cancer Research after serving, since Aug. 2022, as interim director. Mesecar was chosen for the position after a nationwide search.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Keytruda combination improves OS for HER2-positive advanced gastric cancer in phase III trial

The phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival for the first-line treatment of patients with human epidermal growth factor receptor 2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account